Lucigen Corporation Awarded $1.7M in SBIR Grants
Posted: April 21, 2010 - 2:30 PM
April 20, 2010 - Lucigen Corporation is pleased to announce that it has recently been awarded three new grants to fund additional research and development.
The National Institutes of Health has awarded Lucigen $1,764,732 in Small Business Innovation Research grants to be used over two years to develop research tools and diagnostic assays with potential to improve human health. The grants include funding for: 1) development of a simple, sensitive, all-in-one point of care virus-detection system (Phase I award of $400,000), 2) advancement of cloning methods with the goal of identifying novel antibiotics for future clinical development (Phase I award of $164,732), and 3) enhancement of a system for expressing genes which are toxic or unstable in currently available systems (Phase II award of $1,200,000). These three grants will be used to support researchers and enable Lucigen to leverage their expertise in the fields of Genomics and Proteomics.
“We are pleased to receive this additional funding to support our research. These grants will provide Lucigen with the resources we need to rapidly advance our work on new products to support basic and applied medical research, as well as clinical diagnostics” according to David Mead, Ph.D., founder and CEO.
About Lucigen Corporation
Lucigen, located in Middleton, Wisconsin, develops new, more effective life science research products and technologies for gene cloning, genomics, and protein expression. Patented CloneSmart® technology and BigEasy® Cloning Kits dramatically improve DNA cloning reliability and efficiency, allowing successful cloning of genes that have been impossible to capture using standard methods. Lucigen’s exclusive Random Shear BAC Library Cloning Service is being used by genome researchers worldwide to streamline DNA sequencing processes, saving time and research dollars.
Lucigen’s enzyme discovery programs have found new heat-stable enzymes in organisms that inhabit the boiling-hot springs of Yellowstone National Park, which are useful in genomic research, diagnostic and drug discovery applications. The discovery of thermostable carbohydrate-degrading enzymes that can be used by the biofuel industry to increase the efficiency of ethanol production, led to the spinoff from Lucigen of C5-6 Technologies, Inc., in 2006.
For further information, please contact:
David Mead
Lucigen Corporation
2120 W. Greenview Drive
Middleton, WI 53562
Phone: 608-831-9011
FAX: 608-831-9012
Email: dmead@lucigen.com
Web: www.lucigen.com
Medallion Members
- Platinum
- Silver
- Bronze
